- Immune Design (NASDAQ:IMDZ) eases 1% after hours following its announcement that it will cease internal development of cancer vaccine CMB305 and focus its development activities on TLR4 agonist G100.
- The company intends to seek external partners to continue development of CMB305 after a Phase 2 study in synovial sarcoma failed to bear fruit.
- Management will host a conference call at 5:00 pm ET to discuss its plans.